Skip to Primary Navigation

Skip to main content

HHS agency signals drug rebate program redux with request for information

Pill bottles
Photo: George Frey/Getty Images

Kevin Kinsella

3 min read
 Click to share on Facebook (Opens in new window/tab) Click to share on Twitter (Opens in new window/tab) Click to share on LinkedIn (Opens in new window/tab) Click to share on WhatsApp (Opens in new window/tab)

The RFI is the Trump administration’s next move to get its drug pricing rebate program back on track after hospital groups blocked it last year.

The Health Resources and Services Administration (HRSA) has issued a request for information (RFI) for input related to the use of rebates to establish the ceiling price of drugs in the federal 340B program.

Through the RFI, HRSA also seeks to establish the “standards and procedures that should govern the

, , , , , , , , , ,

Get full access, free for a month

Start your 28-day free trial to continue reading and access
all content on GRIP – no payment details required.

Start free trial Sign in

What’s included:

  • Every new article, plus our 5,000+ archive
  • Daily regulatory insight and guidance
  • Exclusive interviews and in-depth analysis
  • Coverage of industry-leading events and conferences
  • All podcasts and videos, featuring industry experts
  • The full set of Rules Navigator tools
  • An ad-free experience